IBIO
iBio, Inc.
There isn't enough reported data to score IBIO yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
IBIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
IBIO's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IBIO PE Valuation
IBIO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
IBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IBIO's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
IBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.26 | +$1.14 |
| Q2 2026 | -$0.32 | +$1.43 |
| Q1 2026 | -$0.58 | +$1.84 |
| Q4 2025 | -$1.01 | +$1.77 |
| Q3 2025 | -$1.40 | +$5.32 |
| Q2 2025 | -$1.75 | +$9.31 |
IBIO lost $0.26 per share over the past year, a smaller loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over IBIO on earnings quality, reporting a profit while its opponent remains loss making.
IBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | +975% |
| Q2 2025 | $200K | +14% |
| Q2 2022 | $61K | -88% |
| Q1 2022 | $1.9M | +154% |
| Q4 2021 | $168K | -76% |
| Q3 2021 | $211K | -49% |
| Q2 2021 | $491K | -56% |
| Q1 2021 | $765K | +697% |
IBIO's revenue is recovering but still below its 2022 peak: $1M last quarter, up 975% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -776% | +5175 points |
| Q3 2025 | -5951% | N/A |
| Q2 2025 | -2599% | -651 points |
| Q4 2024 | -2210% | N/A |
| Q2 2024 | -1948% | N/A |
| Q3 2023 | -10206% | N/A |
| Q2 2022 | -27698% | -25776 points |
| Q1 2022 | -627% | +315 points |
IBIO's operating margin was −776% last quarter, up 1172 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over IBIO on profitability, with a higher operating margin.
IBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | -$3.8M |
| Q2 2026 | -$6.2M | -$1.6M |
| Q1 2026 | -$6.1M | -$3M |
| Q3 2025 | -$5.7M | -$2M |
| Q2 2023 | -$5.5M | +$9.5M |
| Q1 2023 | -$3.7M | +$2.9M |
| Q4 2022 | -$10.6M | +$2.2M |
| Q3 2022 | -$16.4M | -$6M |
IBIO has burned cash in almost every quarter: −$28M over the past year, against −$17M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
IBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +32M shares |
| 1 year | +1437% | +142M shares |
| 3 years | +34185% | +151M shares |
IBIO has 152M diluted shares, up 1437% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over IBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IBIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | -0.0x | Net Cash |
IBIO has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
IBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.3 | Neutral |
| Stochastic | 8.3 | Oversold |
IBIO's weekly RSI is 30 (neutral) and its Stochastic is 8 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IBIO PE vs Healthcare Sector
IBIO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.87 | 13% below |
| 20 week MA | $1.19 | 36% below |
| 50 week MA | $1.68 | 55% below |
| 100 week MA | $1.73 | 56% below |
| 200 week MA | $4.93 | 85% below |
IBIO is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over IBIO on trend strength, trading above more of its moving averages.
IBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.0 | $580.0 | +404% |
| 2021 | $580.0 | $335.0 | -42% |
| 2022 | $335.0 | $8.60 | -97% |
| 2023 | $8.60 | $1.37 | -84% |
| 2024 | $1.37 | $2.45 | +79% |
| 2025 | $2.45 | $1.89 | -23% |
| 2026 YTD | $1.89 | $0.76 | -60% |
IBIO's yearly returns have swung widely, from +404% in 2020 to −97% in 2022. It's down 60% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IBIO on returns for 2026, with the stronger performance.